Logo image of NNOX

NANO-X IMAGING LTD (NNOX) Stock Fundamental Analysis

NASDAQ:NNOX - Nasdaq - IL0011681371 - Common Stock - Currency: USD

4.65  +0.03 (+0.65%)

After market: 4.6305 -0.02 (-0.42%)

Fundamental Rating

4

Taking everything into account, NNOX scores 4 out of 10 in our fundamental rating. NNOX was compared to 103 industry peers in the Health Care Providers & Services industry. While NNOX has a great health rating, there are worries on its profitability. NNOX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NNOX had negative earnings in the past year.
In the past year NNOX has reported a negative cash flow from operations.
In the past 5 years NNOX always reported negative net income.
NNOX had a negative operating cash flow in each of the past 5 years.
NNOX Yearly Net Income VS EBIT VS OCF VS FCFNNOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of NNOX (-27.92%) is worse than 87.38% of its industry peers.
Looking at the Return On Equity, with a value of -31.01%, NNOX is doing worse than 68.93% of the companies in the same industry.
Industry RankSector Rank
ROA -27.92%
ROE -31.01%
ROIC N/A
ROA(3y)-32.63%
ROA(5y)-26.69%
ROE(3y)-37.21%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
NNOX Yearly ROA, ROE, ROICNNOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NNOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NNOX Yearly Profit, Operating, Gross MarginsNNOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

NNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NNOX has more shares outstanding
The number of shares outstanding for NNOX has been increased compared to 5 years ago.
Compared to 1 year ago, NNOX has an improved debt to assets ratio.
NNOX Yearly Shares OutstandingNNOX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NNOX Yearly Total Debt VS Total AssetsNNOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

NNOX has an Altman-Z score of 5.71. This indicates that NNOX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.71, NNOX belongs to the top of the industry, outperforming 85.44% of the companies in the same industry.
NNOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.71
ROIC/WACCN/A
WACC9.01%
NNOX Yearly LT Debt VS Equity VS FCFNNOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.30 indicates that NNOX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 5.30, NNOX belongs to the best of the industry, outperforming 94.17% of the companies in the same industry.
A Quick Ratio of 5.16 indicates that NNOX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.16, NNOX belongs to the best of the industry, outperforming 94.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.16
NNOX Yearly Current Assets VS Current LiabilitesNNOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.36% over the past year.
NNOX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.35%.
NNOX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.51% yearly.
EPS 1Y (TTM)23.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)15.35%
Revenue growth 3Y105.51%
Revenue growth 5YN/A
Sales Q2Q%10.26%

3.2 Future

The Earnings Per Share is expected to grow by 31.01% on average over the next years. This is a very strong growth
NNOX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 82.27% yearly.
EPS Next Y2.04%
EPS Next 2Y21.81%
EPS Next 3Y19.58%
EPS Next 5Y31.01%
Revenue Next Year15.25%
Revenue Next 2Y69.53%
Revenue Next 3Y63.98%
Revenue Next 5Y82.27%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NNOX Yearly Revenue VS EstimatesNNOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NNOX Yearly EPS VS EstimatesNNOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NNOX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NNOX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NNOX Price Earnings VS Forward Price EarningsNNOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNOX Per share dataNNOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NNOX's earnings are expected to grow with 19.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.81%
EPS Next 3Y19.58%

More info and screens

0

5. Dividend

5.1 Amount

NNOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANO-X IMAGING LTD

NASDAQ:NNOX (8/8/2025, 8:00:02 PM)

After market: 4.6305 -0.02 (-0.42%)

4.65

+0.03 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-22 2025-05-22/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners24.71%
Inst Owner Change-0.23%
Ins Owners0.23%
Ins Owner ChangeN/A
Market Cap296.76M
Analysts84
Price Target8.93 (92.04%)
Short Float %9.56%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.22%
Min EPS beat(2)-6.95%
Max EPS beat(2)0.52%
EPS beat(4)2
Avg EPS beat(4)5.41%
Min EPS beat(4)-6.95%
Max EPS beat(4)32.13%
EPS beat(8)4
Avg EPS beat(8)6.25%
EPS beat(12)6
Avg EPS beat(12)-2.37%
EPS beat(16)7
Avg EPS beat(16)-7.84%
Revenue beat(2)0
Avg Revenue beat(2)-26.61%
Min Revenue beat(2)-30.68%
Max Revenue beat(2)-22.54%
Revenue beat(4)0
Avg Revenue beat(4)-25.45%
Min Revenue beat(4)-32.68%
Max Revenue beat(4)-15.9%
Revenue beat(8)0
Avg Revenue beat(8)-25.97%
Revenue beat(12)0
Avg Revenue beat(12)-22.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.5%
PT rev (3m)-25.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.39%
EPS NY rev (1m)-2.94%
EPS NY rev (3m)-7.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.64%
Revenue NY rev (1m)-27.83%
Revenue NY rev (3m)-39.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.7
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB 2.7
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.18
BVpS2.78
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.92%
ROE -31.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.63%
ROA(5y)-26.69%
ROE(3y)-37.21%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.88%
Cap/Sales 27.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.16
Altman-Z 5.71
F-Score4
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)37.93%
Cap/Depr(5y)1552.65%
Cap/Sales(3y)47.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y2.04%
EPS Next 2Y21.81%
EPS Next 3Y19.58%
EPS Next 5Y31.01%
Revenue 1Y (TTM)15.35%
Revenue growth 3Y105.51%
Revenue growth 5YN/A
Sales Q2Q%10.26%
Revenue Next Year15.25%
Revenue Next 2Y69.53%
Revenue Next 3Y63.98%
Revenue Next 5Y82.27%
EBIT growth 1Y-3.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.05%
OCF growth 3YN/A
OCF growth 5YN/A